Title:
NOVEL THERAPEUTIC AGENT RELATING TO THERAPEUTIC AGENT FOR GENETIC RENAL DISEASE ALPORT SYNDROME
Document Type and Number:
WIPO Patent Application WO/2019/039574
Kind Code:
A1
Abstract:
[Problem] To clarify the pathological mechanism of Alport syndrome (AS) for which no specific remedy is known hitherto and to develop a novel therapeutic method therefor which is more efficacious than the conventional symptomatic treatments. [Solution] A therapeutic agent for AS characterized in that AS is treated by regulating metabolism in renal glomeruli. In particular, a biguanide compound or a salt thereof is usable as an active ingredient for regulating the metabolism in renal glomeruli. Still preferably, metformin or a salt thereof and most preferably metformin hydrochloride can be used therefor.
More Like This:
Inventors:
KAI HIROFUMI (JP)
SHUDOU TSUYOSHI (JP)
OOMACHI KOUHEI (JP)
MARY ANN SUICO (JP)
KASEDA MASAHIRO (JP)
SHUDOU TSUYOSHI (JP)
OOMACHI KOUHEI (JP)
MARY ANN SUICO (JP)
KASEDA MASAHIRO (JP)
Application Number:
PCT/JP2018/031257
Publication Date:
February 28, 2019
Filing Date:
August 24, 2018
Export Citation:
Assignee:
UNIV KUMAMOTO NAT UNIV CORP (JP)
International Classes:
A61K45/00; A61K31/155; A61P13/12
Other References:
GOMEZ IG ET AL.: "Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 125, no. 1, January 2015 (2015-01-01), pages 141 - 156, XP009506789, ISSN: 0021-9738, DOI: 10.1172/JCI75852
LUO M ET AL.: "MiRNA-21 mediates the antiangiogenic activity of metformin through targeting PTEN and SMAD7 expression and PI3K/AKT pathway", SCIENTIFIC REPORTS, vol. 7, 23 February 2017 (2017-02-23), pages 43427, XP055679309, ISSN: 2045-2322
MORALES AI ET AL.: "Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway", KIDNEY INTERNATIONAL, vol. 77, no. 10, 2010, pages 861 - 869, XP055679306, ISSN: 0085-2538
FENG Y ET AL.: "Metformin attenuates renal fibrosis in both AMPKa2-dependent and independent manners", CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, vol. 44, no. 6, June 2017 (2017-06-01), pages 648 - 655, XP055679297, ISSN: 0305-1870
SHEN Y ET AL.: "Metformin Prevents Renal Fibrosis in Mice with Unilateral Ureteral Obstruction and Inhibits Ang II-Induced ECM Production in Renal Fibroblasts", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 17, 2016, pages 146, XP055679295, ISSN: 1422-0067
SAYERS R ET AL.: "Role for transforming growth factor-betal in alport renal disease progression", KIDNEY INTERNATIONAL, vol. 56, no. 5, 1999, pages 1662 - 1673, XP055679292, ISSN: 0085-2538
KASEDA, MASAHIRO ET AL.: "Protective effects against progressive glomerulonephritis by metformin", LECTURE ABSTRACTS OF THE 39TH SYMPOSIUM ON INTERACTION BETWEEN BIOMEMBRANE AND MEDICINE, vol. 39, 26 October 2017 (2017-10-26), pages 60 - 61, XP009520433, ISSN: 0919-2131
KASEDA, MASAHIRO ET AL.: "Establishment of novel method for curing hereditary renal disease, Alport syndrome, by means of antidiabetic drug, Metfromin", JAPANESE JOURNAL OF PEDIATRIC NEPHROLOGY, vol. 31, no. 1, 24 May 2018 (2018-05-24), pages 99, XP009520443, ISSN: 0915-2245
LUO M ET AL.: "MiRNA-21 mediates the antiangiogenic activity of metformin through targeting PTEN and SMAD7 expression and PI3K/AKT pathway", SCIENTIFIC REPORTS, vol. 7, 23 February 2017 (2017-02-23), pages 43427, XP055679309, ISSN: 2045-2322
MORALES AI ET AL.: "Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway", KIDNEY INTERNATIONAL, vol. 77, no. 10, 2010, pages 861 - 869, XP055679306, ISSN: 0085-2538
FENG Y ET AL.: "Metformin attenuates renal fibrosis in both AMPKa2-dependent and independent manners", CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, vol. 44, no. 6, June 2017 (2017-06-01), pages 648 - 655, XP055679297, ISSN: 0305-1870
SHEN Y ET AL.: "Metformin Prevents Renal Fibrosis in Mice with Unilateral Ureteral Obstruction and Inhibits Ang II-Induced ECM Production in Renal Fibroblasts", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 17, 2016, pages 146, XP055679295, ISSN: 1422-0067
SAYERS R ET AL.: "Role for transforming growth factor-betal in alport renal disease progression", KIDNEY INTERNATIONAL, vol. 56, no. 5, 1999, pages 1662 - 1673, XP055679292, ISSN: 0085-2538
KASEDA, MASAHIRO ET AL.: "Protective effects against progressive glomerulonephritis by metformin", LECTURE ABSTRACTS OF THE 39TH SYMPOSIUM ON INTERACTION BETWEEN BIOMEMBRANE AND MEDICINE, vol. 39, 26 October 2017 (2017-10-26), pages 60 - 61, XP009520433, ISSN: 0919-2131
KASEDA, MASAHIRO ET AL.: "Establishment of novel method for curing hereditary renal disease, Alport syndrome, by means of antidiabetic drug, Metfromin", JAPANESE JOURNAL OF PEDIATRIC NEPHROLOGY, vol. 31, no. 1, 24 May 2018 (2018-05-24), pages 99, XP009520443, ISSN: 0915-2245
Attorney, Agent or Firm:
KAWAGUCHI Takayoshi (JP)
Download PDF: